FLC Capital Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.59M | Sell |
66,092
-2,760
| -4% | -$72.2K | 0.26% | 64 |
|
|
2026
Q1 | $1.93M | Sell |
68,852
-1,634
| -2% | -$43.5K | 0.35% | 52 |
|
|
2025
Q4 | $1.76M | Sell |
70,486
-1,261
| -2% | -$31.8K | 0.32% | 53 |
|
|
2025
Q3 | $1.83M | Buy |
71,747
+14,055
| +24% | +$347K | 0.35% | 49 |
|
|
2025
Q2 | $1.4M | Sell |
57,692
-798
| -1% | -$18.6K | 0.29% | 56 |
|
|
2025
Q1 | $1.48M | Buy |
58,490
+10,879
| +23% | +$285K | 0.33% | 49 |
|
|
2024
Q4 | $1.26M | Buy |
47,611
+8,839
| +23% | +$240K | 0.29% | 52 |
|
|
2024
Q3 | $1.12M | Buy |
38,772
+5,556
| +17% | +$162K | 0.26% | 56 |
|
|
2024
Q2 | $929K | Sell |
33,216
-3,450
| -9% | -$95K | 0.23% | 60 |
|
|
2024
Q1 | $1.02M | Buy |
36,666
+2,316
| +7% | +$64.3K | 0.26% | 56 |
|
|
2023
Q4 | $989K | Sell |
34,350
-12,907
| -27% | -$390K | 0.27% | 56 |
|
|
2023
Q3 | $1.57M | Sell |
47,257
-7,438
| -14% | -$263K | 0.47% | 42 |
|
|
2023
Q2 | $2.01M | Sell |
54,695
-3,808
| -7% | -$148K | 0.59% | 39 |
|
|
2023
Q1 | $2.39M | Sell |
58,503
-3,482
| -6% | -$150K | 0.73% | 31 |
|
|
2022
Q4 | $3.18M | Sell |
61,985
-1,973
| -3% | -$94.6K | 0.99% | 25 |
|
|
2022
Q3 | $2.8M | Sell |
63,958
-3,020
| -5% | -$147K | 0.97% | 27 |
|
|
2022
Q2 | $3.51M | Sell |
66,978
-1,746
| -3% | -$89K | 1.17% | 21 |
|
|
2022
Q1 | $3.56M | Sell |
68,724
-1,692
| -2% | -$87.8K | 1% | 27 |
|
|
2021
Q4 | $4.16M | Sell |
70,416
-1,419
| -2% | -$70.3K | 1.16% | 20 |
|
|
2021
Q3 | $3.09M | Sell |
71,835
-2,281
| -3% | -$101K | 0.91% | 30 |
|
|
2021
Q2 | $2.9M | Sell |
74,116
-91
| -0.1% | -$3.54K | 0.85% | 29 |
|
|
2021
Q1 | $2.69M | Buy |
74,207
+14,630
| +25% | +$519K | 0.84% | 35 |
|
|
2020
Q4 | $2.19M | Buy |
59,577
+6,997
| +13% | +$257K | 0.73% | 36 |
|
|
2020
Q3 | $1.87M | Buy |
52,580
+9,852
| +23% | +$345K | 0.68% | 41 |
|
|
2020
Q2 | $1.4M | Buy |
42,728
+6,801
| +19% | +$231K | 0.55% | 45 |
|
|
2020
Q1 | $1.12M | Buy |
35,927
+4,996
| +16% | +$170K | 0.52% | 33 |
|
|
2019
Q4 | $1.15M | Sell |
30,931
-86
| -0.3% | -$3.06K | 0.46% | 34 |
|
|
2019
Q3 | $1.06M | Buy |
31,017
+977
| +3% | +$35.5K | 0.45% | 35 |
|
|
2019
Q2 | $1.23M | Buy |
30,040
+5,330
| +22% | +$212K | 0.51% | 35 |
|
|
2019
Q1 | $996K | Buy |
24,710
+4,981
| +25% | +$199K | 0.45% | 34 |
|
|
2018
Q4 | $817K | Buy |
+19,729
| New | +$819K | 0.55% | 30 |
|
Other funds holding PFE
FLC Capital Advisors's PFE Position: Q2 2026 in Review
FLC Capital Advisors reduced its Pfizer (PFE) stake by 4% in Q2 2026, selling an estimated $72.2K and leaving 66,092 shares worth $1.59M. The position accounts for 0.26% of the portfolio, ranked #64.
FLC Capital Advisors first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $4.16M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- FLC Capital Advisors held 66,092 shares of Pfizer worth $1.59M as of Q2 2026.
- FLC Capital Advisors sold 2,760 Pfizer shares in Q2 2026, an estimated $72.2K.
- Pfizer made up 0.26% of FLC Capital Advisors's portfolio in Q2 2026, its #64 holding.
- FLC Capital Advisors first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- FLC Capital Advisors's Pfizer position peaked at $4.16M in Q4 2021.
- 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on FLC Capital Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.